Reproxalap is a Small Molecule owned by Aldeyra Therapeutics, and is involved in 24 clinical trials, of which 22 were completed, and 2 are ongoing.
Reproxalap exhibits therapeutic intervention by inhibiting the formation of toxic metabolites (aldehydes) that accumulate in the back of the eye, thereby inhibiting the disruption of cellular processes. It results in inhibition of NF-kappa B activation, cytokine release, apoptosis, mitochondrial dysfunction, and inhibiting the degradation of tear lipids. This leads to increase in the tear production and prevention of eye disease.
The revenue for Reproxalap is expected to reach a total of $3.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Reproxalap NPV Report.
Reproxalap is originated and owned by Aldeyra Therapeutics.
Reproxalap (ADX-102) is under development for allergic conjunctivitis, dry eye syndrome and coronavirus disease 2019 (COVID-19). It is administered through oral, dermal and ophthalmic routes. It is developed based on pro-inflammatory reactive aldehyde species (RASP) scavenger platform. It is also under development for oral formulation indications including amino acid metabolism disorder including succinic semialdehyde dehydrogenase deficiency (SSADH) (oral formulation).
The drug candidate was also under development for the treatment of sjogren-larsson syndrome, discoid lupus erythematosus, congenital ichthyosis in subjects with dermatitis including contact dermatitis and allergic dermatitis, ocular inflammation including ocular rosacea with meibomian gland dysfunction, radiation-induced oral mucositis and acute non-infectious anterior uveitis.
Aldeyra Therapeutics Overview
Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
The operating loss of the company was US$56.2 million in FY2021, compared to an operating loss of US$36.4 million in FY2020. The net loss of the company was US$57.8 million in FY2021, compared to a net loss of US$37.6 million in FY2020.
Quick View – Reproxalap
|Highest Development Stage|